290 related articles for article (PubMed ID: 28427179)
1. Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.
Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grövdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellström-Lindberg E; Ungerstedt J
Oncotarget; 2017 Apr; 8(17):28812-28825. PubMed ID: 28427179
[TBL] [Abstract][Full Text] [Related]
2. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
3. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
4. DNA methyltransferases as targets for cancer therapy.
Ghoshal K; Bai S
Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
Silverman LR
Leuk Res; 2009 Dec; 33 Suppl 2():S18-21. PubMed ID: 20004792
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes.
Yang Y; Li J; Geng Y; Liu L; Li D
J Clin Lab Anal; 2021 Feb; 35(2):e23597. PubMed ID: 33080073
[TBL] [Abstract][Full Text] [Related]
7. Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
Tsujioka T; Yokoi A; Itano Y; Takahashi K; Ouchida M; Okamoto S; Kondo T; Suemori S; Tohyama Y; Tohyama K
Sci Rep; 2015 Nov; 5():16709. PubMed ID: 26577244
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.
Grövdal M; Karimi M; Tobiasson M; Reinius L; Jansson M; Ekwall K; Ungerstedt J; Kere J; Greco D; Hellström-Lindberg E
Leukemia; 2014 Feb; 28(2):411-3. PubMed ID: 24025691
[No Abstract] [Full Text] [Related]
9. Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome.
Wong YF; Micklem CN; Taguchi M; Itonaga H; Sawayama Y; Imanishi D; Nishikawa S; Miyazaki Y; Jakt LM
Stem Cells Transl Med; 2014 Oct; 3(10):1188-98. PubMed ID: 25122688
[TBL] [Abstract][Full Text] [Related]
10. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Schmelz K; Sattler N; Wagner M; Lübbert M; Dörken B; Tamm I
Leukemia; 2005 Jan; 19(1):103-11. PubMed ID: 15510208
[TBL] [Abstract][Full Text] [Related]
11. A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome.
Asano M; Ohyashiki JH; Kobayashi-Kawana C; Umezu T; Imanishi S; Azuma K; Akahane D; Fujimoto H; Ito Y; Ohyashiki K
Drug Des Devel Ther; 2019; 13():1821-1833. PubMed ID: 31239639
[No Abstract] [Full Text] [Related]
12. Gene Expression and DNA Methylation Profiling Suggest Potential Biomarkers for Azacitidine Resistance in Myelodysplastic Syndrome.
Kim DY; Shin DY; Oh S; Kim I; Kim EJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731939
[TBL] [Abstract][Full Text] [Related]
13. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
[TBL] [Abstract][Full Text] [Related]
14. Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes.
Matsumoto T; Murakami Y; Yoshida-Sakai N; Katsuchi D; Kanazawa K; Okamura T; Imamura Y; Ono M; Kuwano M
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731802
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
[TBL] [Abstract][Full Text] [Related]
16. Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.
Tsujioka T; Yokoi A; Uesugi M; Kishimoto M; Tochigi A; Suemori S; Tohyama Y; Tohyama K
Exp Hematol; 2013 Feb; 41(2):189-97. PubMed ID: 23085465
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic changes in the myelodysplastic syndrome.
Issa JP
Hematol Oncol Clin North Am; 2010 Apr; 24(2):317-30. PubMed ID: 20359628
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.
Kazachenka A; Young GR; Attig J; Kordella C; Lamprianidou E; Zoulia E; Vrachiolias G; Papoutselis M; Bernard E; Papaemmanuil E; Kotsianidis I; Kassiotis G
Genome Med; 2019 Dec; 11(1):86. PubMed ID: 31870430
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome.
Tran HT; Kim HN; Lee IK; Kim YK; Ahn JS; Yang DH; Lee JJ; Kim HJ
J Korean Med Sci; 2011 Feb; 26(2):207-13. PubMed ID: 21286011
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
Noguera-Castells A; Campillo-Marcos I; Davalos V; García-Prieto CA; Valcárcel D; Molero A; Palomo L; Gattermann N; Wulfert M; Chaparro-González L; Solé F; Cabezón M; Jiménez-Lorenzo MJ; Xicoy B; Zamora L; De Stefano A; Casalin I; Finelli C; Follo MY; Esteller M
Br J Haematol; 2024 May; 204(5):1838-1843. PubMed ID: 38471524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
